Iovance Biotherapeutics Initiates Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma Read more about Iovance Biotherapeutics Initiates Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma
Iovance Biotherapeutics Reports Second Quarter and First Half 2022 Financial Results and Corporate Updates Read more about Iovance Biotherapeutics Reports Second Quarter and First Half 2022 Financial Results and Corporate Updates
Iovance Biotherapeutics to Host Second Quarter Financial Results Conference Call and Webcast on Thursday, August 4, 2022 Read more about Iovance Biotherapeutics to Host Second Quarter Financial Results Conference Call and Webcast on Thursday, August 4, 2022
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Read more about Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics Provides Cervical Cancer Program Updates Following End of Phase 2 Meeting with U.S. Food and Drug Administration (FDA) Read more about Iovance Biotherapeutics Provides Cervical Cancer Program Updates Following End of Phase 2 Meeting with U.S. Food and Drug Administration (FDA)
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Read more about Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics Appoints Wendy L. Dixon, Ph.D., to Board of Directors Read more about Iovance Biotherapeutics Appoints Wendy L. Dixon, Ph.D., to Board of Directors
Iovance Biotherapeutics to Present at Upcoming Conferences Read more about Iovance Biotherapeutics to Present at Upcoming Conferences
Iovance Biotherapeutics Announces Positive Clinical Data for Lifileucel in Advanced Melanoma Read more about Iovance Biotherapeutics Announces Positive Clinical Data for Lifileucel in Advanced Melanoma
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Read more about Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)